N
AQST icon

Natixis’s Aquestive Therapeutics AQST Stock Holding History

Natixis’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108K Buy
+25,963
New +$109K ﹤0.01% 993

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Natixis's AQST Position: Q2 2026 in Review

Natixis opened a new position in Aquestive Therapeutics (AQST) in Q2 2026: 25,963 shares worth $108K. The stake represents ﹤0.01% of the portfolio and ranks #993 among its holdings.

184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Natixis held 25,963 shares of Aquestive Therapeutics worth $108K as of Q2 2026.
  • Aquestive Therapeutics was a new Natixis position in Q2 2026.
  • Aquestive Therapeutics made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #993 holding.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.